REG - Frontier IP Group - Appointment of Chief Financial Officer

Frontier IPAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE9058Ca&default-theme=true

RNS Number : 9058C  Frontier IP Group plc  05 May 2026

RNS: 9058C

AIM: FIPP

5 May 2026

Frontier IP Group plc

("Frontier IP" or the "Group")

Appointment of Chief Financial Officer

Frontier IP, a specialist in commercialising intellectual property, is pleased
to announce the appointment of Shaun Claydon as Chief Financial Officer and
Company Secretary with immediate effect.

Shaun is an ICAEW-qualified chartered accountant with extensive experience in
corporate finance, scaling businesses, and delivering successful exits. He
brings more than 20 years' experience in senior financial leadership roles,
including more than 15 years at board-level, with a focus on fundraising,
mergers and acquisitions ("M&A"), and growth strategy.

Shaun has held board-level positions in a number of private and public
companies, most recently as Chief Financial Officer at Actimed Therapeutics,
where he co-led a Series B equity funding round securing a multi-million
investment for clinical programmes. Prior to this Shaun served as Chief
Financial Officer of Destiny Pharma for six years between 2018 and 2024.
Before transitioning to executive roles, Shaun gained extensive experience in
financial consultancy and senior corporate finance roles including at HSBC
Investment Banking, BDO LLP, Evolution Securities plc and PwC.

He is currently a non-executive director of spirits group Distil plc.

Further to the announcement made by the Company on 6 November 2025, Jo Stent,
previous Chief Financial Officer of the Group, has now stepped down from the
Group's Board. However, Jo will remain employed with the Group for an
additional short period of time to ensure an orderly handover of
responsibilities to Shaun and to provide additional support on both a
corporate level and with certain portfolio companies.

Neil Crabb, Chief Executive of Frontier IP, said: "I am delighted to welcome
Shaun to our Board of Directors and to the wider Group. Shaun brings
significant expertise and experience, particularly in areas of key focus for
our portfolio companies, including equity fundraising, IPOs and M&A. He
will play a vital role in the next stage of our growth as we focus on
developing our portfolio companies towards exit."

Shaun Claydon, Chief Financial Officer, said: "I am very pleased to be joining
Frontier IP at this important stage of its development. I look forward to
helping the Group and its portfolio companies realise their full potential. I
look forward to working with Jo over the coming weeks to ensure a seamless
handover of responsibilities."

Further regulatory disclosures

The following additional information is provided in accordance with Rule 17
and Schedule Two Paragraph (g) of the AIM Rules for Companies.

Shaun Claydon, aged 57, is, or has been, a director or partner of the
following companies or partnerships during the previous five years:

 

 Current directorships and/or partnerships  Former directorships and/or partnerships within the last five years
 Distil plc                                 Destiny Pharma Limited

                                            Destiny Pharma (Brighton) Limited

                                            Destiny Pharma EU Limited (Ireland)

 

Shaun Claydon was previously a director of Destiny Pharma Limited ("Destiny")
(formerly known as Destiny Pharma plc) until 30 September 2024. Destiny
appointed an administrator on 21 August 2024 and was placed into creditors'
voluntary liquidation on 1 August 2025.

 

ENQUIRIES

 

 Frontier IP Group Plc

 Neil Crabb, Chief Executive                                           neil@frontierip.co.uk (mailto:neil@frontierip.co.uk)

 Andrew Johnson, Communications & Investor Relations                   M: 07415 888 425

 Company website: www.frontierip.co.uk (http://www.frontierip.co.uk)   andrew.johnson@frontierip.co.uk (mailto:andrew.johnson@frontierip.co.uk)

 Allenby Capital Limited (Nominated Adviser)                           T: 0203 328 5656

 Nick Athanas

 Singer Capital Markets (Broker)                                       T: 0207 496 3000

 James Fischer

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual
property and accelerating its development through a range of commercialisation
services. A critical part of the Group's work is involving relevant industry
partners at an early stage of development to ensure technology meets real
world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQZLFBQELZBBE



            Copyright 2019 Regulatory News Service, all rights reserved